MedTrace Logo

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

NCT05991388 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2026-02-20

No results posted yet for this study

Summary

The Glo-BNHL trial is trying to find better medicines for children and young people with B-cell non-Hodgkin Lymphoma (B-NHL) that does not go away (refractory B-NHL) or does but comes back again (relapsed B-NHL). B-NHL is a type of cancer that develops inside or outside of lymph nodes (glands) and organs such as the liver or spleen. Examples of B-NHL are Burkitt Lymphoma and Diffuse Large B Cell Lymphoma, which may be other names used to describe this type of cancer. It is very difficult to cure relapsed or refractory B-NHL. The medicines used now are very powerful with many side effects and only cure around 30 in every 100 children treated. It is very important that investigators quickly find better medicines for these children and young people.

The Glo-BNHL trial will include three groups of children and young people, each given a new medicine (either alone or with chemotherapy). The investigators are looking to make sure the new medicines are safe and that they work to treat the cancer. If the medicine in one group does not work for a child in the trial, then they may be able to join a different group to have another new medicine.

Experts from around the world will carefully pick the medicines most likely to be helpful to be part of the trial. If one of the new medicines seems not to be working as well as hoped then the investigators will take it out of the trial as soon as possible. This will let other new medicines be added to the trial and tested. If a medicine does seem to be working well, then it will continue in the trial to make sure it really is the most useful medicine available.

Children from around the world will be invited to take part in the trial. The investigators will then check on them for at least two years after they finish the trial treatment to look for possible side effects of the new medicine.

Conditions

  • B-cell Non Hodgkin Lymphoma

Interventions

DRUG

Odronextamab

CD20xCD3 bispecific antibody

DRUG

Loncastuximab tesirine

CD-19-directed antibody-drug conjugate

DRUG

Rituximab

Modified R-ICE chemotherapy

DRUG

Ifosfamide

Modified R-ICE chemotherapy

DRUG

Carboplatin

Modified R-ICE chemotherapy

DRUG

Etoposide

Modified R-ICE chemotherapy

DRUG

Etoposide Phosphate

Modified R-ICE (Treatment Arm II)

DRUG

Dexamethasone

Modified R-ICE chemotherapy

BIOLOGICAL

CAR T-cells (TBC)

Modified R-ICE chemotherapy

Sponsors & Collaborators

Principal Investigators

  • Amos Burke · University of Birmingham

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-02
Primary Completion
2031-05-01
Completion
2033-05-01
FDA Drug
Yes

Countries

  • Australia
  • Austria
  • Belgium
  • Netherlands
  • New Zealand
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05991388 on ClinicalTrials.gov